Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) meddelade den 4 mars år 2025 att Bolaget har t...
Redeye comments on BioInvent's fourth-quarter report 2024.
Med en välfylld kassa efter en framgångsrik emission, flera pågående dialoger med möjliga samarbetsp...
7% premium to last 3-month average, slightly below last close Equates to 2.
Redeye returns with a more in-depth take on the Q3 results.
Redeye updates on Northbaze Group following its Q4 results, which were weaker than expected in terms...
Redeye is making rather small changes to its forecasts following the Q4 report.
Redeye initiates coverage of GomSpace, a leading smallsat provider with a strong market position and...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har publicerat Koncernens delår...
Redeye returns with an updated view of Saniona following the Q4 report and recent events in the comp...
Redeye provides a research update following MindArk’s softer-than-expected Q4 report.
Flowscape levererar sin näst högsta omsättning i det fjärde kvartalet och uppvisar ett positivt röre...
Creditas, som utgör cirka 40% av VEFs investeringsportfölj, presenterade ännu en stark rapport för d...
ODI Pharma AB (“ODI Pharma” or the ”Company”) published on February 27th the company’s Q2-report for...
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe and t...
Redeye provides an update on Jumpgate following its weaker-than-expected Q4 results.
The company's EBITDA was close to our expectation in Q4, and investment in the new quay in Paldiski ...
Svag försäljning men förbättrad lönsamhet Nettoomsättningen minskade med 19,9 procent, främst på gru...
We believe that the company's revenue growth of 40% y/y and record-high EBIT margin of 15% in Q4 202...
Redeye initiates coverage on GiG Software which is an online gambling platform supplier with an attr...